In the second quarter of this year, the Hungarian pharmaceutical company Gedeon Richter's sales and profit exceeded analysts' expectations: sales increased by 23.7% to HUF 192.9 billion and profit after tax more than doubled to HUF 77.1 billion in April-June compared to the same period last year, the company said on the website of the […]
Gedeon Richter Plc. and Searchlight Pharma Inc. have announced that Searchlight has assumed all Canadian distribution and promotional activities for Evra®, a transdermal contraceptive patch. This transition, which covers regulatory, distribution and promotional responsibilities in Canada, stems from the acquisition of ex-US rights to the Evra brand by Richter from Janssen Pharmaceutica NV, a wholly-owned […]
AbbVie and Gedeon Richter Plc. have announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases. The collaboration is based on the results of preclinical research carried out by Richter and includes several new chemical entities selected for development. AbbVie and Richter […]
AbbVie, the partner company of the Hungarian pharmaceutical firm Gedeon Richter Plc., has submitted a supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR®) to the U.S. Food and Drug Administration (FDA) for the adjunctive treatment of major depressive disorder (MDD) in patients who are receiving ongoing antidepressant therapy. The submission is supported by results from […]
“Sales revenues in the first nine months were up on a year-on-year basis in most markets in both HUF and EUR terms, fueled by growth in the specialty portfolio, in particular higher Vraylar® and Evra® royalties. This broad-based strength in revenue performance was translated into a solid bottomline also ex-Vraylar®, despite higher spending on R&D […]
The Hungarian pharmaceutical firm Gedeon Richter Plc. announced this Monday that it signed a multi-party agreement to divest its wholesale operation to Grin-Farm S.R.L. and its retail operations to BIRIVOFARM S.R.L., both in the Republic of Moldova. Richter as a majority owner of both the wholesale and the retail operations is entitled to approximately 62% […]
Gedeon Richter Plc. has announced that it extended its existing licensing agreement with AbbVie, originally dated 2004, for the development and commercialization of its own-developed molecule, cariprazine. The initial agreement covered the territories of the USA and Canada and was extended in 2019 to include certain countries in Latin America. The present agreement further expands […]
The Hungarian pharmaceutical Gedeon Richter Plc. has announced that the European Commission has granted approval for the marketing authorization of the novel combined oral contraceptive containing 15 mg estetrol and 3 mg drospirenone. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) […]
As the world enters into the second year of the COVID-19 pandemic, the Hungarian pharmaceutical company Gedeon Richter Plc. continues to regularly provide a brief update of its impact on the health and wellbeing of its employees and its operations at large. According to OECD Statistics, global GDP declined by 4.2 % in 2020 due […]
In its 2020 report to the Budapest Stock Exchange, the Hungarian pharmaceutical company Gedeon Richter Plc. states that the company managed to service its customers on time and in full also into the last quarter of the reported year despite a sharp increase in COVID-19 case numbers in its countries of operation. Additional protective measures […]
The Hungarian pharmaceutical company Richter and the Belgian pharma firm Mithra strengthen their partnership with the signing of a license and supply agreement for the commercialization of a novel oral contraceptive to Latin America. Gedeon Richter Plc. and Estetra S.A, the wholly owned subsidiary of Mithra Pharmaceuticals, have announced that they extended their partnership and […]
A three-year price record for the shares of the Hungarian pharmaceutical company Gedeon Richter was broken on Monday: the price rose above HUF 7,300 at the Budapest Stock Exchange. The company is one of the winners of the coronavirus epidemic, it is helped by the weakening of the Hungarian currency, and its sales are not […]
For the first time in history, an original molecule invented by a CEE headquartered pharmaceutical company (Gedeon Richter's Vraylar), reached blockbuster status in the USA in the first half of 2020. "Thanks to the outstanding performance of our trusted partner Abbvie, Vraylar’s turnover exceeded USD 1 billion in Q2, which triggered the receipt of a […]
Richter's atypical antipsychotic, Reagila, containing the active ingredient cariprazine, was awarded the title of Drug of the Year 2019 by the Hungarian Society for Experimental and Clinical Pharmacology (HUNPHAR). Each year, the prestigious award recognizes the most advanced and effective products that have made a significant breakthrough in the cure of a disease. The award […]
